Shares of AVI Biopharma (NASDAQ:AVII) fell 24% early Monday after the company announced mixed results from a Phase II study for its drug candidate eteplirsen in the treatment of Duchenne muscular dystrophy in boys.AVI BioPharma (NASDAQ:AVII) has potential upside of 184.5% based on a current price of $1.16 and an average consensus analyst price target of $3.3.AVI BioPharma is currently above its 50-day moving average (MA) of $1.14 and above its 200-day of $1.09.In the last five trading sessions, the 50-day MA has climbed 5.93% while the 200-day MA has risen 0.36%.